Platelet aggregation inhibitors. II - N-heterocyclic aldoxime methiodides (1).
On the basis of an hypothesis according to which suitable nucleophilic agents may convert adenosine diphosphate (ADP) into adenosine monophosphate (AMP) and adenosine, well known inhibitors of ADP-induced platelet aggregation, some N-heterocyclic aldoxime methiodides were tested as inhibitors of ADP-induced rabbit platelet aggregation. Several 1-aryl-2-hydroxyiminomethly-3-methylimidazolium iodides significantly inhibit in vitro and in vivo-in vitro ADP-induced rabbit platelet aggregation.
D000244:Adenosine Diphosphate; D000818:Animals; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D010091:Oximes / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits
D006571:Heterocyclic Compounds; D010091:Oximes; D000244:Adenosine Diphosphate